» Articles » PMID: 1749210

Detoxification Pathways in the Liver

Overview
Publisher Wiley
Date 1991 Jan 1
PMID 1749210
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

The liver plays an important rôle in protecting the organism from potentially toxic chemical insults through its capacity to convert lipophiles into more water-soluble metabolites which can be efficiently eliminated from the body via the urine. This protective ability of the liver stems from the expression of a wide variety of xenobiotic biotransforming enzymes whose common underlying feature is their ability to catalyse the oxidation, reduction and hydrolysis (Phase I) and/or conjugation (Phase II) of functional groups on drug and chemical molecules. The broad substrate specificity, isoenzyme multiplicity and inducibility of many of these enzyme systems make them particularly well adapted to handling the vast array of different chemical structures in the environment to which we are exposed daily. However, some chemicals may also be converted to more toxic metabolites by certain of these enzymes, implying that variations in the latter may be important predisposing factors for toxicity. Pharmacogenetic defects of xenobiotic biotransformation enzymes, a subclass of inborn errors of metabolism which are manifested only upon drug challenge, introduce marked variation into human populations for the pharmacokinetics and pharmacodynamics of therapeutic and toxic agents, and thus may have important clinical consequences for drug efficacy and toxicity.

Citing Articles

Risk Assessment Arising from the Exposure of Terrestrial Vertebrates to Soil Contamination: Learning from Field Lizards of the Genus.

Scudiero R, Chianese T, Creti P, Rosati L J Xenobiot. 2025; 15(1).

PMID: 39997364 PMC: 11855989. DOI: 10.3390/jox15010021.


Delivering miR-23b-3p by small extracellular vesicles to promote cell senescence and aberrant lipid metabolism.

Jin Y, Sun G, Chen B, Feng S, Tang M, Wang H BMC Biol. 2025; 23(1):41.

PMID: 39934790 PMC: 11817603. DOI: 10.1186/s12915-025-02143-9.


Inhibition of GABARAP or GABARAPL1 prevents aminoglycoside- induced hearing loss.

Li J, Oh S, Liu C, Zhao B Proc Natl Acad Sci U S A. 2025; 122(7):e2416453122.

PMID: 39928869 PMC: 11848329. DOI: 10.1073/pnas.2416453122.


In Vitro Investigation of Biological and Toxic Effects of 4-Octylphenol on Human Cells.

Romanelli A, Montefusco A, Sposito S, Scafuri B, Caputo I, Paolella G Int J Mol Sci. 2024; 25(23).

PMID: 39684746 PMC: 11641860. DOI: 10.3390/ijms252313032.


Complex system modelling reveals oxalate homeostasis is driven by diverse oxalate-degrading bacteria.

Mukherjee S, Batagello C, Adler A, Agudelo J, Zampini A, Suryavanshi M bioRxiv. 2024; .

PMID: 39553961 PMC: 11565779. DOI: 10.1101/2024.10.28.620613.


References
1.
Grant D, Blum M, Beer M, Meyer U . Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol. 1991; 39(2):184-91. View

2.
Blum M, Grant D, Demierre A, Meyer U . N-acetylation pharmacogenetics: a gene deletion causes absence of arylamine N-acetyltransferase in liver of slow acetylator rabbits. Proc Natl Acad Sci U S A. 1989; 86(23):9554-7. PMC: 298535. DOI: 10.1073/pnas.86.23.9554. View

3.
Grant D, Lottspeich F, Meyer U . Evidence for two closely related isozymes of arylamine N-acetyltransferase in human liver. FEBS Lett. 1989; 244(1):203-7. DOI: 10.1016/0014-5793(89)81193-7. View

4.
Evans D . N-acetyltransferase. Pharmacol Ther. 1989; 42(2):157-234. DOI: 10.1016/0163-7258(89)90036-3. View

5.
Grant D, Morike K, Eichelbaum M, Meyer U . Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest. 1990; 85(3):968-72. PMC: 296518. DOI: 10.1172/JCI114527. View